M&A

News

Galapagos' chief executive Paul Stoffels

Galapagos unveils plan to split, hiving off its drugs unit

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.

Market Access

Graphic of an upward trajectory arrow with woman and telescope atop

The biopharma outlook for 2025: Opportunities and challenges

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how cap

News

London-listed Poolbeg discussing Hookipa merger

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.

News

Regeneron builds in eye disease tech with Oxular takeover

Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.

News

Hutchmed cashes in a Chinese JV to help fund its pipeline

Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.

News

Amid BIOSECURE Act speculation, WuXi AppTec sells unit

WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum

Galapagos unveils plan to split, hiving off its drugs unit

The biopharma outlook for 2025: Opportunities and challenges

London-listed Poolbeg discussing Hookipa merger

Regeneron builds in eye disease tech with Oxular takeover

Hutchmed cashes in a Chinese JV to help fund its pipeline

Amid BIOSECURE Act speculation, WuXi AppTec sells unit

Are Makary's priority review vouchers about to be canned?

Securing your ROI: Turning post-acquisition integration into...

M&A

Editor's Picks